Molecular basis for a link between complement and the vascular complications of diabetes

被引:193
作者
Acosta, J
Hettinga, J
Flückiger, R
Krumrei, N
Goldfine, A
Angarita, L
Halperin, J
机构
[1] Harvard Univ, Sch Med, Lab Membrane Transport, Boston, MA 02115 USA
[2] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA
[3] Joslin Diabet Ctr, Boston, MA 02115 USA
关键词
D O I
10.1073/pnas.97.10.5450
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Activated terminal complement proteins C5b to C9 form the membrane attack complex (MAC) pore. Insertion of the MAC into endothelial cell membranes causes the release of growth factors that stimulate tissue growth and proliferation. The complement regulatory membrane protein CD59 restricts MAC formation. Because increased cell proliferation characterizes the major chronic vascular complications of human diabetes and because increased glucose levels in diabetes cause protein glycation and impairment of protein function, we investigated whether glycation could inhibit CD59. Glycation-inactivation of CD59 would cause increased MAC deposition and MAC-stimulated cell proliferation. Here, we report that (i) human CD59 is glycated in vivo, (ii) glycated human CD59 loses its MAC-inhibitory function, and (iii) inactivation of CD59 increases MAC-induced growth factor release from endothelial cells. We demonstrate by site-directed mutagenesis that residues K41 and H44 form a preferential glycation motif in human CD59. The presence of this glycation motif in human CD59, but not in CD59 of other species, may help explain the distinct propensity of humans to develop vascular proliferative complications of diabetes.
引用
收藏
页码:5450 / 5455
页数:6
相关论文
共 47 条
[1]   TERMINAL COMPLEMENT PROTEINS C5B-9 RELEASE BASIC FIBROBLAST GROWTH-FACTOR AND PLATELET-DERIVED GROWTH-FACTOR FROM ENDOTHELIAL-CELLS [J].
BENZAQUEN, LR ;
NICHOLSONWELLER, A ;
HALPERIN, JA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 179 (03) :985-992
[2]   Mutational analysis of the active site and antibody epitopes of the complement-inhibitory glycoprotein, CD59 [J].
Bodian, DL ;
Davis, SJ ;
Morgan, BP ;
Rushmere, NK .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 185 (03) :507-516
[3]   NONENZYMATIC GLYCOSYLATION AND THE PATHOGENESIS OF DIABETIC COMPLICATIONS [J].
BROWNLEE, M ;
VLASSARA, H ;
CERAMI, A .
ANNALS OF INTERNAL MEDICINE, 1984, 101 (04) :527-537
[4]   AMINOGUANIDINE PREVENTS DIABETES-INDUCED ARTERIAL-WALL PROTEIN CROSS-LINKING [J].
BROWNLEE, M ;
VLASSARA, H ;
KOONEY, A ;
ULRICH, P ;
CERAMI, A .
SCIENCE, 1986, 232 (4758) :1629-1632
[5]  
BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315
[6]  
BUNN HF, 1981, SCIENCE, V213, P222, DOI 10.1126/science.12192669
[7]  
Censullo P, 1994, Semin Immunol, V6, P81, DOI 10.1006/smim.1994.1012
[8]  
CERIELLO A, 1987, DIABETES METAB, V13, P16
[9]   Pathogenesis of glomerular damage in glomerulonephritis [J].
Couser, WG .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1998, 13 :10-15
[10]   CD59, AN LY-6-LIKE PROTEIN EXPRESSED IN HUMAN LYMPHOID-CELLS, REGULATES THE ACTION OF THE COMPLEMENT MEMBRANE ATTACK COMPLEX ON HOMOLOGOUS CELLS [J].
DAVIES, A ;
SIMMONS, DL ;
HALE, G ;
HARRISON, RA ;
TIGHE, H ;
LACHMANN, PJ ;
WALDMANN, H .
JOURNAL OF EXPERIMENTAL MEDICINE, 1989, 170 (03) :637-654